AIM ImmunoTech Future Growth

Future criteria checks 2/6

AIM ImmunoTech is forecast to grow earnings and revenue by 0.2% and 75.9% per annum respectively while EPS is expected to grow by 8.1% per annum.

Key information

0.2%

Earnings growth rate

8.1%

EPS growth rate

Biotechs earnings growth	27.6%
Revenue growth rate	75.9%
Future return on equity	n/a
Analyst coverage	Low
Last updated	10 Dec 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

NYSEAM:AIM - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	8	-32	N/A	N/A	1
12/31/2025	3	-24	N/A	-19	2
12/31/2024	0	-17	N/A	-8	1
9/30/2024	0	-24	-21	-21	N/A
6/30/2024	0	-28	-24	-23	N/A
3/31/2024	0	-31	-23	-22	N/A
12/31/2023	0	-29	-22	-21	N/A
9/30/2023	0	-21	-18	-18	N/A
6/30/2023	0	-19	-17	-17	N/A
3/31/2023	0	-19	-17	-17	N/A
12/31/2022	0	-19	-16	-16	N/A
9/30/2022	0	-21	-16	-16	N/A
6/30/2022	0	-18	-15	-14	N/A
3/31/2022	0	-19	-14	-14	N/A
12/31/2021	0	-19	-15	-14	N/A
9/30/2021	0	-17	-12	-11	N/A
6/30/2021	0	-17	-11	-11	N/A
3/31/2021	0	-14	-11	-10	N/A
12/31/2020	0	-14	-11	-10	N/A
9/30/2020	0	-12	-10	-10	N/A
6/30/2020	0	-11	-10	-9	N/A
3/31/2020	0	-10	-11	-11	N/A
12/31/2019	0	-9	-9	-9	N/A
9/30/2019	0	-10	-9	-9	N/A
6/30/2019	0	-10	-10	-10	N/A
3/31/2019	0	-10	-10	-10	N/A
12/31/2018	0	-10	-11	-11	N/A
9/30/2018	0	-10	-9	-9	N/A
6/30/2018	0	-8	N/A	-8	N/A
3/31/2018	0	-8	N/A	-7	N/A
12/31/2017	0	-8	N/A	-8	N/A
9/30/2017	0	-7	N/A	-9	N/A
6/30/2017	0	-9	N/A	-10	N/A
3/31/2017	0	-8	N/A	-9	N/A
12/31/2016	0	-8	N/A	-7	N/A
9/30/2016	0	-9	N/A	-9	N/A
6/30/2016	0	-10	N/A	-9	N/A
3/31/2016	0	-14	N/A	-13	N/A
12/31/2015	0	-15	N/A	-16	N/A
9/30/2015	0	-17	N/A	-17	N/A
6/30/2015	0	-17	N/A	-17	N/A
3/31/2015	0	-17	N/A	-15	N/A
12/31/2014	0	-17	N/A	-14	N/A
9/30/2014	0	-16	N/A	-13	N/A
6/30/2014	0	-17	N/A	-13	N/A
3/31/2014	0	-16	N/A	-14	N/A
12/31/2013	0	-16	N/A	-17	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AIM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AIM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AIM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AIM's revenue (75.9% per year) is forecast to grow faster than the US market (9.2% per year).

High Growth Revenue: AIM's revenue (75.9% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if AIM's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/26 00:45
End of Day Share Price	2024/12/24 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

AIM ImmunoTech Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Edward Woo	Ascendiant Capital Markets LLC
Ling Wang	Chardan Capital Markets, LLC
Jason McCarthy	Maxim Group

AIM ImmunoTech Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Consensus EPS estimates upgraded to US$0.30 loss

Price target increased by 19% to US$4.25

Consensus EPS estimates fall by 15%

Consensus revenue estimates increase by 52%

Price target decreased by 30% to US$2.75

Consensus EPS estimates fall by 12%

Recent updates

Less than half of directors are independent

AIM ImmunoTech Receives Non-Compliance Letter from NYSE American

Ted Kellner Provides Information to the Shareholders

Consensus EPS estimates upgraded to US$0.30 loss

Ted D. Kellner Files Definitive Proxy Statement with Securities and Exchange Commission

AIM Immunotech Inc. Appoints William A. Carter as Chairman of Scientific Advisory Board

Kellner Group Issues Press Release to Urge AIM Immunotech Stockholders to Vote the Gold Card

New major risk - Revenue and earnings growth

New major risk - Financial position

Kellner Group Urges Immediate Change at AIM Immunotech Inc

AIM ImmunoTech Inc., Annual General Meeting, Dec 17, 2024

AIM ImmunoTech Inc., Annual General Meeting, Dec 17, 2024

Price target increased by 19% to US$4.25

AIM ImmunoTech Inc. has filed a Follow-on Equity Offering in the amount of $1.25632 million.

AIM ImmunoTech Inc. has filed a Follow-on Equity Offering in the amount of $1.25632 million.

AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

Ted D. Kellner Sends a Notice to AIM ImmunoTech

Consensus EPS estimates fall by 15%

AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

Second quarter 2024 earnings released: US$0.035 loss per share (vs US$0.10 loss in 2Q 2023)

Todd Deutsch Sends Notice of Intent to Nominate Candidates to AIM ImmunoTech Board

AIM ImmunoTech Inc. Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of A Combination Therapy

AIM ImmunoTech Inc. has filed a Follow-on Equity Offering in the amount of $2.047668 million.

AIM ImmunoTech Inc. has filed a Follow-on Equity Offering in the amount of $2.047668 million.

Consensus revenue estimates increase by 52%

First quarter 2024 earnings released: US$0.12 loss per share (vs US$0.076 loss in 1Q 2023)

AIM Immunotech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

New minor risk - Shareholder dilution

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

AIM ImmunoTech Inc. to Report Q4, 2023 Results on Apr 02, 2024

Price target decreased by 30% to US$2.75

AIM ImmunoTech Inc. announced that it has received $3.30125 million in funding

Aim Immunotech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions

AIM ImmunoTech Inc., Annual General Meeting, Dec 29, 2023

AIM ImmunoTech Inc. Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions

Consensus EPS estimates fall by 12%

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen

AIM ImmunoTech Inc. Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen for the Treatment of Advanced Recurrent Ovarian Cancer

AIM ImmunoTech Inc., Annual General Meeting, Dec 01, 2023

AIM ImmunoTech Inc., Annual General Meeting, Dec 01, 2023

Kellner Group to Proceed with AIM Director Nominations and Proxy Solicitation

Consensus revenue estimates increase by 15%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

AIM Immunotech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen(R) for the Treatment of Post-Covid Conditions

AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen(R) for the Treatment of Post-COVID Conditions

AIM ImmunoTech Inc. Announces Authorizations from Competent Authority and Ethics Board in the Netherlands to Begin Phase 1B/2 Study Evaluating Ampligen®? (Rintatolimod) in Combination with Astrazeneca's Imfinzi (Durvalumab) for the Treatment of Pancreatic Cancer

AIM ImmunoTech Inc. Outlines Recent Significant Progress Across Clinical Development Pipeline and Provides Update on Positive Pre-Clinical and IP Developments

Price target decreased by 7.8% to US$4.92

Price target decreased by 7.7% to US$5.00

First quarter 2023 earnings released: US$0.076 loss per share (vs US$0.08 loss in 1Q 2022)

Consensus revenue estimates decrease by 83%, EPS upgraded

AIM ImmunoTech Inc. Announces the Netherlands Patent Office (Octrooicentrum Nederland) Grants A Utility Patent Covering Rugged dsRNA, A Double-Stranded RNA Product Related to Ampligen® (Rintatolimod)

Executive Vice Chairman recently bought US$50k worth of stock

AIM ImmunoTech Inc. Promotes Christopher McAleer from Deputy Scientific Officer to Scientific Officer

Aim Immunotech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy Subjects

Consensus revenue estimates fall by 34%

Insufficient new directors

AIM ImmunoTech Inc. Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen

ASFV Committee Issues a Statement on Ruling in Delaware Action

ASFV Committee Reveals Troubling Statements Made by Entrenched AIM Board Uncovered Through Discovery in Delaware Action

Jonathan Thomas Jorgl Issues an Investor Presentation to Shareholders of AIM ImmunoTech

Jonathan Jorgl Provides Information to Shareholders of AIM ImmunoTech

AIM Immunotech Announces FDA Clearance of IND Application to Evaluate Ampligen in Phase 2 Clinical Study for the Treatment of Post-Covid Conditions

Jonathan Thomas Jorgl Mails a Letter to Shareholders of AIM ImmunoTech

AIM ImmunoTech Inc., Annual General Meeting, Nov 03, 2022

AIM ImmunoTech Inc., Annual General Meeting, Nov 03, 2022

AIM ImmunoTech Inc. and Study Collaborator Roswell Park Commence Enrollment in an NCI-Funded Phase 2 Clinical Trial Evaluating Ampligen® (Rintatolimod) in Primary Pd-1/Pd-L1 Resistant Melanoma

Consensus revenue estimates fall by 23%